Download PDF

1. Company Snapshot

1.a. Company Description

Siegfried Holding AG engages in the life sciences business worldwide.The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products.It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production.


In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases.Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products.The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

Show Full description

1.b. Last Insights on SFZN

Siegfried Holding AG faced challenges in recent months, with its latest earnings report revealing flat revenue growth of CHF619.5m in the first half of 2025. The company's EPS lagged expectations, potentially concerning investors. Moreover, a recent intrinsic value estimate suggests a fair value of CHF73.82, which may imply limited upside potential. With no recent announcements on share buybacks or new product launches, the company's fundamentals appear to be under scrutiny. According to a recent report, the company's strong fundamentals may be temporarily overshadowed by short-term weakness.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Estimating The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)

Nov -17

Source:

Card image cap

Will Weakness in Siegfried Holding AG's (VTX:SFZN) Stock Prove Temporary Given Strong Fundamentals?

Sep -12

Source:

Card image cap

Siegfried Holding First Half 2025 Earnings: Revenues Beat Expectations, EPS Lags

Aug -26

Source:

Card image cap

With 49% stake, Siegfried Holding AG (VTX:SFZN) seems to have captured institutional investors' interest

Aug -18

Source:

Card image cap

Health Care Roundup: Market Talk

Apr -02

Source:

Card image cap

Siegfried Holding AG (XSWX:SFZN) Full Year 2024 Earnings Call Highlights: Strong Profit Growth ...

Feb -19

Source:

Card image cap

Health Care Roundup: Market Talk

Apr -02

Source:

Card image cap

Lonza Taps Siegfried Holding’s Wolfgang Wienand as Next CEO

Apr -02

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.65%)

6. Segments

Drug Substances

Expected Growth: 5%

Siegfried Holding AG's Drug Substances segment growth is driven by increasing demand for complex APIs, strategic partnerships, and capacity expansions. The company's expertise in HPAPIs and ADCs, coupled with a strong pipeline of new projects, contributes to its growth. Additionally, the rising need for outsourcing in the pharmaceutical industry and Siegfried's ability to provide integrated services also support its growth momentum.

Drug Products

Expected Growth: 7%

Siegfried Holding AG's 7% growth in drug products is driven by increasing demand for contract manufacturing services, expansion into emerging markets, and strategic partnerships. Additionally, investments in capacity expansion, process optimization, and quality enhancements have improved operational efficiency, contributing to revenue growth.

7. Detailed Products

Active Pharmaceutical Ingredients (APIs)

Siegfried Holding AG develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.

Contract Manufacturing

Siegfried Holding AG offers contract manufacturing services for pharmaceutical and biotech companies, providing customized solutions for drug development and production.

Pharmaceutical Intermediates

Siegfried Holding AG develops and manufactures pharmaceutical intermediates, which are used as building blocks for the production of APIs.

Custom Synthesis

Siegfried Holding AG provides custom synthesis services, developing and manufacturing complex molecules for pharmaceutical and biotech companies.

Analytical Services

Siegfried Holding AG offers analytical services, providing testing and characterization of pharmaceutical products and APIs.

8. Siegfried Holding AG's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Siegfried Holding AG is moderate, as there are some alternatives available in the market, but they are not very attractive to customers.

Bargaining Power Of Customers

The bargaining power of customers for Siegfried Holding AG is low, as customers have limited options and the company has a strong brand presence.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Siegfried Holding AG is moderate, as the company has some negotiating power, but suppliers also have some bargaining power.

Threat Of New Entrants

The threat of new entrants for Siegfried Holding AG is high, as the industry is attractive and there are low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for Siegfried Holding AG is high, as the industry is highly competitive and there are many players competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 36.33%
Debt Cost 3.95%
Equity Weight 63.67%
Equity Cost 7.15%
WACC 5.98%
Leverage 57.05%

11. Quality Control: Siegfried Holding AG passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Ipsen

A-Score: 5.5/10

Value: 5.0

Growth: 6.0

Quality: 7.7

Yield: 1.2

Momentum: 6.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Hikma Pharmaceuticals

A-Score: 5.3/10

Value: 4.9

Growth: 4.4

Quality: 6.1

Yield: 5.0

Momentum: 3.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Almirall

A-Score: 5.0/10

Value: 4.3

Growth: 2.2

Quality: 4.3

Yield: 2.5

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Sobi

A-Score: 4.8/10

Value: 3.1

Growth: 7.3

Quality: 7.4

Yield: 0.0

Momentum: 5.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Siegfried Holding

A-Score: 4.4/10

Value: 4.4

Growth: 7.4

Quality: 5.5

Yield: 0.6

Momentum: 1.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Alvotech

A-Score: 2.9/10

Value: 5.1

Growth: 5.8

Quality: 5.7

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

71.8$

Current Price

71.8$

Potential

-0.00%

Expected Cash-Flows